411 related articles for article (PubMed ID: 33937032)
1. Preclinical Evaluation of Carfilzomib for Infant
Cheung LC; de Kraa R; Oommen J; Chua GA; Singh S; Hughes AM; Ferrari E; Ford J; Chiu SK; Stam RW; Kees UR; Malinge S; Kotecha RS
Front Oncol; 2021; 11():631594. PubMed ID: 33937032
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.
Swift L; Jayanthan A; Ruan Y; Anderson R; Boklan J; Trippett T; Narendran A
Target Oncol; 2018 Dec; 13(6):779-793. PubMed ID: 30446871
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract][Full Text] [Related]
4. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
Front Oncol; 2022; 12():863329. PubMed ID: 35677155
[TBL] [Abstract][Full Text] [Related]
5. Decitabine mildly attenuates
Schneider P; Castro PG; Pinhanços SM; Kerstjens M; van Roon EH; Essing AHW; Dolman MEM; Molenaar JJ; Pieters R; Stam RW
EJHaem; 2020 Nov; 1(2):527-536. PubMed ID: 35844991
[No Abstract] [Full Text] [Related]
6. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia.
Burke MJ; Ziegler DS; Bautista F; Attarbaschi A; Gore L; Locatelli F; M O'Brien M; Pauly M; Kormany WN; Tian S; Morris CL; Baruchel A
Pediatr Blood Cancer; 2022 Dec; 69(12):e29999. PubMed ID: 36215217
[TBL] [Abstract][Full Text] [Related]
7. High-Throughput Drug Library Screening in Primary
Wander P; Arentsen-Peters STCJM; Vrenken KS; Pinhanҫos SM; Koopmans B; Dolman MEM; Jones L; Garrido Castro P; Schneider P; Kerstjens M; Molenaar JJ; Pieters R; Zwaan CM; Stam RW
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327440
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric
Kerstjens M; Garrido Castro P; Pinhanços SS; Schneider P; Wander P; Pieters R; Stam RW
Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34201500
[TBL] [Abstract][Full Text] [Related]
10. Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line.
Hosseini MS; Mohammadi MH; Vahabpour Roudsari R; Jafari L; Mashati P; Gharehbaghian A
Iran J Pharm Res; 2019; 18(Suppl1):132-145. PubMed ID: 32802094
[TBL] [Abstract][Full Text] [Related]
11. Systematic
Karsa M; Ronca E; Bongers A; Mariana A; Moles E; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Kavallaris M; Haber M; Norris MD; Henderson MJ; Xiao L; Somers K
Front Oncol; 2021; 11():779859. PubMed ID: 35127484
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
Leukemia; 2021 May; 35(5):1279-1290. PubMed ID: 33623141
[TBL] [Abstract][Full Text] [Related]
13. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
[TBL] [Abstract][Full Text] [Related]
14. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
15. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
16. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract][Full Text] [Related]
17. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
[TBL] [Abstract][Full Text] [Related]
19. Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia.
Richter A; Lange S; Holz C; Brock L; Freitag T; Sekora A; Knuebel G; Krohn S; Schwarz R; Hinz B; Murua Escobar H; Junghanss C
Cell Death Discov; 2022 Jul; 8(1):302. PubMed ID: 35778418
[TBL] [Abstract][Full Text] [Related]
20. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
